Abstract
Jeremy Rifkin, the author-activist who's never met an engineered gene he liked, kicked off a new campaign against the use of human genetic data on 21 May in Washington, D.C. With endorsements from members of women's health movements in 69 nations, he unveiled a campaign that will attack the patenting of breast cancer genes BRCA1 and BRCA2 and push for new laws to limit access to human genetic data in research, medicine, and commerce. But like other coalitions he has put together in the past to oppose genetic engineering, the members of this coalition may have different agendas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
